These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:
- Albireo Pharma (ALBO), 5,741% surge in interest
- Calithera Biosciences (CALA), 2,056% surge in interest
- Revance Therapeutics (RVNC), 1,811% surge in interest
- Cerus (CERS), 1,472% surge in interest
- Nanostring Technologies (NSTG), 772% surge in interest
Pipeline and key clinical candidates for these companies:
Albireo Pharma is focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis, or PFIC, and in Europe for the treatment of PFIC. Bylvay is also being developed to treat other rare pediatric cholestatic liver diseases with a completed Phase 3 trial in Alagille syndrome, or ALGS, an ongoing Phase 3 study in biliary atresia, as well as Open-label Extension studies for PFIC and ALGS. The company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008.
Calithera Biosciences is a precision oncology biopharmaceutical company developing targeted therapies to "redefine treatment for biomarker-specific patient populations." Calithera is advancing a pipeline of investigational, small-molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers for which there are currently limited treatment options.
Revance is a biotechnology company whose aesthetics portfolio includes Daxxify for injection, the RHA Collection of dermal fillers, and OPUL, the "first-of-its-kind Relational Commerce platform for aesthetic practices." Revance has also partnered with Viatris to develop a biosimilar to Botox, which will compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating Daxxify in two debilitating conditions, cervical dystonia and upper limb spasticity.
Cerus Corporation is dedicated to "safeguarding the world’s blood supply and aims to become the preeminent global blood products company," it has said. The company develops and supplies technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and "remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components," Cerus states. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
NanoString Technologies says it offers "an ecosystem of innovative discovery and translational research solutions" to map the universe of biology – including the GeoMx Digital Spatial Profiler, the CosMx Spatial Molecular Imager and the AtoMx Spatial Informatics Platform. The CosMx SMI and AtoMx SIP platforms are expected to launch in 2022.
Recent news on these stocks:
January 9
Ipsen (IPSEY) and Albireo announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo. The lead medicine in Albireo’s pipeline is Bylvay, a potent, once-daily, oral, non-systemic ileal bile acid transport inhibitor, or IBATi. As part of the transaction, Ipsen will also acquire Albireo’s clinical stage asset A3907, a novel oral systemic apical sodium-dependent bile acid transporter inhibitor currently in development for adult cholestatic liver disease, such as primary sclerosing cholangitis, which could complement Ipsen’s existing development programs. In addition to Bylvay and A3907, Albireo’s pipeline includes A2342, an oral systemic sodium-taurocholate co-transporting peptide inhibitor being evaluated for viral and cholestatic diseases, which is moving ahead in investigational new drug, or IND-enabling trials.
Calithera Biosciences announced that its board has determined, after extensive consideration of potential strategic alternatives, that it is in the best interests of its shareholders to dissolve the company and liquidate its assets, following an orderly wind down of the company’s operations. In order to reduce costs and in connection with the planned dissolution, Calithera is discontinuing all clinical development programs and reducing its workforce, including the termination of most employees by the end of the first quarter.
Revance announced that it expects preliminary unaudited fourth quarter Collection revenue to be between $34M-$35M, representing an approximately 45% increase from the same period last year, and FY22 preliminary unaudited RHA Collection revenue of between $106.5M-$107.5M, representing an approximately 50% increase from FY21.
Cerus reported preliminary Q4 revenue $44M against a consensus of $42.4M. "Cerus’ commercial execution in the fourth quarter of 2022 was consistent with our strong performance throughout the first three quarters of the year. We believe the continued growth in demand for the INTERCEPT Blood System, particularly in the U.S., reflected the ongoing resiliency of our business as well as the integral role played by pathogen reduction in safeguarding the global blood supply," stated William Greenman, Cerus’ CEO.
About “Biotech Alert”
The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.
This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 15-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.
This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NSTG:
